Русский 
English 
Deutsch 
Español 
العربية 
中文 
Türkçe 
Français 
Italiano 
What is lupus arthritis
Systemic lupus erythematosus (SLE) is an autoimmune disease in which the immune system attacks its own tissues. Joints are affected in 90% of SLE patients — this is one of the earliest and most common symptoms. Lupus arthritis is usually non-erosive (unlike rheumatoid), but prolonged disease can lead to deformity — Jaccoud's arthropathy.
Autoimmune inflammation
Anti-DNA antibodies and immune complexes deposit in the synovial membrane, causing chronic inflammation. Unlike RA, cartilage destruction is slow — but accumulates over time.
Ligament damage
Lupus damages ligaments and joint capsule — leading to instability and subluxations. Jaccoud's arthropathy: deformity without erosions — "reducible" but painful.
Osteonecrosis (avascular necrosis)
Consequence of steroid therapy and antiphospholipid syndrome. Affects femoral heads, knee joints. Requires early intervention to preserve the joint. → Learn more
Tendinitis & tendon ruptures
Lupus weakens tendons — increased risk of spontaneous ruptures (especially Achilles, rotator cuff). Whether regenerative treatment is an option in this condition is assessed by the clinic doctor. → Learn more
Forms of joint involvement in SLE
Non-erosive polyarthritis (90%)
Symmetric involvement of small joints of hands, wrists, knees. Morning stiffness >30 minutes. Swelling, tenderness. X-ray — no erosions (unlike RA). Migratory pain pattern.
Jaccoud's arthropathy (5–15%)
Joint deformity without bone erosions: ulnar deviation, "swan neck," Z-deformity of thumb. Reducible — but progresses without treatment. Cause — ligament and capsule damage.
Erosive arthritis "Rhupus" (1–5%)
Rare overlap of SLE and RA: true erosions on X-ray + seropositivity for RF and ACPA. More aggressive course. Requires combined baseline therapy.
Avascular necrosis (10–30%)
Consequence of steroid therapy and APS. Most common — femoral heads. Groin pain on walking. MRI detects early stages. Regenerative treatment can halt progression at stage I–II.
Diagnosis of lupus arthritis
Laboratory activity assessment
SLEDAI-2K (SLE activity index). Anti-dsDNA, complement C3/C4, ESR, CRP. regenerative procedure is performed only with SLEDAI <6 and normal complement.
Joint ultrasound
Visualization of synovitis, effusion, tenosynovitis. Power Doppler — assessment of inflammation activity. Dynamic monitoring of treatment effectiveness. Used for targeted injections.
MRI
Early diagnosis of avascular necrosis (before X-ray). Assessment of cartilage, ligaments, meniscus. Differential diagnosis with RA (erosions). Mandatory before MFAT decision.
Radiography
Exclusion of erosions, assessment of deformity in Jaccoud's arthropathy. Staging of avascular necrosis by Ficat. Follow-up monitoring (every 12 months).
Lupus arthritis: treatment options and what is known about them
The treatment plan is made by the clinic doctor after an examination and a review of your images. The table shows the options usually discussed for this diagnosis and how well they have been studied.
| Option | What to expect | How well studied |
|---|---|---|
| Treatment by a rheumatologist | Disease-modifying or specific drug therapy — the basis of treatment | Well studied, recommended |
| Exercise therapy and physiotherapy | Reduces pain, strengthens muscles, improves function; the basis of treatment | Moderate evidence |
| Painkillers and NSAIDs | Ease pain during flare-ups; long-term use is limited by side effects | Moderate evidence |
| Corticosteroid injection | Quickly reduces inflammation and pain, the effect is often temporary; frequent injections are undesirable | Limited or conflicting evidence |
| PRP / CGF | — | Not usually used for this diagnosis |
We send your request to several partner clinics. Some will suggest conservative treatment or injections, others surgery; each clinic quotes its own conditions and price. We help you compare the options.
Regenerative methods: realistic expectations
In inflammatory joint diseases the key is treating the cause with a rheumatologist: disease-modifying drugs for rheumatoid arthritis and ankylosing spondylitis, lowering uric acid for gout. An intra-articular corticosteroid injection helps with a flare in a single joint. Regenerative injections do not affect the inflammatory process and have hardly been studied for these diagnoses.
When surgery is discussed. Surgery (synovectomy, joint replacement) is discussed for joint destruction or persistent synovitis despite drug treatment.
If an injection helps, the effect usually builds up over 6–12 weeks, and the result is assessed after 2–3 months. No clinic can guarantee a result.
Safety & contraindications
When regenerative treatment can be performed
SLEDAI <6, normal complement (C3, C4), stable baseline therapy dose >3 months, no active nephritis or serositis. Rheumatologist coordination mandatory.
Absolute contraindications
Active lupus nephritis (class III–V). Thrombotic APS in acute phase. SLEDAI >6. Decreased complement. Active infection. Oncology.
Relative contraindications
Anticoagulant use (discontinue 3–5 days prior). Thrombocytopenia <50×10⁹/L. High steroid doses (>20 mg prednisone) — reduce first. Recent baseline therapy change (<3 months).
Why autologous cells are safe
Patient's own cells are used (blood for CGF, adipose tissue for MFAT) — no immune conflict risk. MSCs have immunomodulatory, not immunostimulatory effect. Numerous studies confirm safety in autoimmune diseases.
Rehabilitation and recovery
In lupus arthritis, recovery depends above all on controlling disease activity. Regular gentle mobility and strengthening exercise, swimming and walking help preserve joint function; load is reduced during flares. After a joint injection, 1–2 days of rest are usually recommended. Sun protection and regular rheumatology check-ups are important.
Scientific evidence
Studies of regenerative methods show mixed results. Clinic physicians rely on research including the following:
- Fanouriakis A et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis, 2024.
- Kaul A et al. Systemic lupus erythematosus. Nat Rev Dis Primers, 2016.
Next: Treatment methods · Treatment costs · Contact a coordinator
Frequently asked questions
RegenPAS is a patient service centre in Munich, not a clinic. We review your images and symptoms and send a request to several partner clinics at once. Clinics that can accept you send their own conditions and price; prices differ between clinics, and you choose the option that suits you. The coordinator replies within 24 hours, and a clinic physician’s preliminary opinion follows in 1–3 business days. We then arrange the appointment, visa invitation, interpreter, transfers and accommodation. Treatment decisions are made by the clinic physician. Contact a coordinator.
Your MRI (or CT, X-ray) report and the images if you have them, plus a short description of your symptoms and previous treatment. Send them via the form on the website — the assessment is free and without obligation: the coordinator replies within 24 hours, and the clinic physician’s preliminary opinion follows in 1–3 business days.
The cost depends on the method, the diagnostics needed and the clinic itself: prices differ between clinics. We request offers from several clinics and send you their conditions and quotes so you can compare. Price guidance is on the treatment cost page. For an outpatient procedure, 2–3 days in Munich are usually enough: examination, procedure and follow-up visit.